Differences in 23S ribosomal RNA mutations between wild-type and mutant macrolide-resistant Chlamydia trachomatis isolates

Jiang,Yong; Zhu,Hui; Yang,Li‑Na; Liu,Yuan‑Jun; Hou,Shu‑Ping; Qi,Man‑Li; Liu,Quan‑Zhong

doi:10.3892/etm.2015.2595

Differences in 23S ribosomal RNA mutations between wild-type and mutant macrolide-resistant Chlamydia trachomatis isolates

Authors:
- Yong Jiang
- Hui Zhu
- Li‑Na Yang
- Yuan‑Jun Liu
- Shu‑Ping Hou
- Man‑Li Qi
- Quan‑Zhong Liu
View Affiliations

Affiliations: Department of Dermatology, The Second Hospital of Tianjin Medical University, Heping, Tianjin 300052, P.R. China, Department of Dermatology, General Hospital of Tianjin Medical University, Heping, Tianjin 300052, P.R. China
Published online on: June 24, 2015 https://doi.org/10.3892/etm.2015.2595
Pages: 1189-1193

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine the in vitro susceptibility of wild-type and mutant clinical isolates of Chlamydia (C.) trachomatis strains to erythromycin, azithromycin and josamycin, and to identify the resistance-conferring 23S ribosomal (r)RNA mutations in the isolates. The wild‑type resistant isolates were defined as those with minimum inhibitory concentration values above the tissue concentration of the antibiotic in the urogenital system. Furthermore, all resistant C. trachomatis isolates were exposed to sub‑inhibitory concentrations of macrolides, and 13 resistant mutants were selected following serial passages. Among the 8 wild‑type isolates that were resistant to erythromycin, 3 isolates had a mutation at T2611C in the 23S rRNA gene while the others did not show any 23S rRNA mutations. The selected mutant isolates showed a 4‑ to 16‑fold reduction in in vitro sensitivities. With regard to the mutant strains, the T2611C mutation was found in 10 isolates, A2057G mutation in 6 isolates, and A2059G mutation in 1 isolate. Thus, the macrolide‑resistant isolates of the wild‑type strain had different mutations from those selected by exposure to sub‑inhibitory concentrations of macrolides. Also, since 23S rRNA mutations were not identified in certain isolates, it was considered that other molecular mechanisms may also be responsible for the macrolide resistance of C. trachomatis.

View Figures

View References

1	Centers for Disease Control and Prevention, . Workowski KA and Berman SA: Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 55:1–94. 2006.PubMed/NCBI
2	Hogan RJ, Mathews SA, Mukhopadhyay S, Summersgill JT and Timms P: Chlamydial persistence: Beyond the biphasic paradigm. Infect Immun. 72:1843–855. 2004. View Article : Google Scholar : PubMed/NCBI
3	Mpiga P and Ravaoarinoro M: Chlamydia trachomatis persistence: An update. Microbiol Res. 161:9–19. 2006. View Article : Google Scholar : PubMed/NCBI
4	Senn L, Hammerschlag MR and Greub G: Therapeutic approaches to Chlamydia infections. Expert Opin Pharmacother. 6:2281–2290. 2005. View Article : Google Scholar : PubMed/NCBI
5	Somani J, Bhullar VB, Workowski KA, Farshy CE and Black CM: Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis. 181:1421–1427. 2000. View Article : Google Scholar : PubMed/NCBI
6	Horner P: The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection. Sex Transm Infect. 82:340–343. 2006. View Article : Google Scholar : PubMed/NCBI
7	Samra Z, Rosenberg S, Soffer Y and Dan M: In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis. 39:177–179. 2001. View Article : Google Scholar : PubMed/NCBI
8	Sor F and Fukuhara H: Identification of two erythromycin resistance mutations in the mitochondrial gene coding for the large ribosomal RNA in yeast. Nucleic Acids Res. 10:6571–6577. 1982. View Article : Google Scholar : PubMed/NCBI
9	Sigmund CD, Ettayebi M and Morgan EA: Antibiotic resistance mutations in 16S and 23S ribosomal RNA genes of Escherichia coli. Nucleic Acids Res. 12:4653–4663. 1984. View Article : Google Scholar : PubMed/NCBI
10	Meier A, Heifets L, Wallace RJ Jr, et al: Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: Observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis. 174:354–360. 1996. View Article : Google Scholar : PubMed/NCBI
11	Scarpellini P, Carrera P, Cavallero A, Cernuschi M, Mezzi G, Testoni PA, Zingale A and Lazzarin A: Direct detection of Helicobacter pylori mutations associated with macrolide resistance in gastric biopsy material taken from human immunodeficiency virus-infected subjects. J Clin Microbiol. 40:2234–2237. 2002. View Article : Google Scholar : PubMed/NCBI
12	Vester B and Douthwaite S: Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother. 45:1–12. 2001. View Article : Google Scholar : PubMed/NCBI
13	Misyurina OY, Chipitsyna EV, Finashutina YP, Lazarev VN, Akopian TA, Savicheva AM and Govorun VM: Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides. Antimicrob Agents Chemother. 48:1347–1349. 2004. View Article : Google Scholar : PubMed/NCBI
14	Binet R and Maurelli AT: Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. Antimicrob Agents Chemother. 51:4267–4275. 2007. View Article : Google Scholar : PubMed/NCBI
15	Shang S, Xia L, Shao C, et al: In vitro effects of various antibiotics alone and in combination with other antibiotics against Chlamydia trachomatis. Chin J Dermatol. 38:282–284. 2005.
16	Welsh LE, Gaydos CA and Quinn TC: In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 36:291–294. 1992. View Article : Google Scholar : PubMed/NCBI
17	Suchland RJ, Geisler WM and Stamm WE: Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother. 47:636–642. 2003. View Article : Google Scholar : PubMed/NCBI
18	Clinical and Laboratory Standards Institute (CLSI), . Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Sulement (M100-S19). CLSI; Wayne, PA, USA: 2009
19	Michéa-Hamzehpour M, Kahr A and Pechère JC: In vitro stepwise selection of resistance to quinolones, beta-lactams and amikacin in nosocomial gram-negative bacilli. Infection. 22:(Sul 2). S105–S110. 1994. View Article : Google Scholar : PubMed/NCBI